Mindwalk Holdings Corp (HYFT)

$1.14 +0.01 (0.77%)
Market Cap 52.16M
Revenue (ttm) 17.59M
Net Income (ttm) -21.69M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -123.31%
Debt to Equity Ratio 0.00
Volume 367,544
Avg Vol 499,740
Day's Range N/A - N/A
Shares Out 46.16M
Stochastic %K 3%
Beta 0.51
Analysts Sell
Price Target $4.00

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology
Sector: Healthcare
Phone: 800 620 4187
Address:
Industrious 823 Congress Ave, Suite 300, Austin, United States
NyseDayTrader
NyseDayTrader Mar. 2 at 8:13 PM
$HYFT Days of speculative rises are done with Bath. She needs to deliver!
0 · Reply
Crewm8te
Crewm8te Mar. 2 at 7:51 PM
$HYFT
0 · Reply
falcon_trader11
falcon_trader11 Mar. 2 at 7:06 PM
$HYFT
0 · Reply
Brandon70454
Brandon70454 Mar. 2 at 5:36 PM
$HYFT stay down until next week...I'll triple investment again.
0 · Reply
DollerADay
DollerADay Mar. 2 at 4:07 PM
$HYFT
0 · Reply
Brandon70454
Brandon70454 Mar. 2 at 3:35 PM
$HYFT tripled original investment...lets go!
0 · Reply
TheDuck23
TheDuck23 Mar. 2 at 2:22 PM
$HYFT going to be adding big time today
1 · Reply
NyseDayTrader
NyseDayTrader Mar. 2 at 9:42 AM
$HYFT
1 · Reply
Twills08
Twills08 Mar. 1 at 4:53 PM
$HYFT Company has been awfully quiet lately….
1 · Reply
PrimePorter
PrimePorter Mar. 1 at 7:51 AM
$HYFT
0 · Reply
Latest News on HYFT
MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

Mar 2, 2026, 8:31 AM EST - 7 hours ago

MindWalk Holdings Corp. to Report Third Quarter Fiscal Year 2026 Financial Results on March 12, 2026

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

Jan 27, 2026, 12:01 AM EST - 4 weeks ago

MindWalk Applies HYFT® Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

Jan 14, 2026, 8:00 AM EST - 6 weeks ago

MindWalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic TDP-43 in Neurodegenerative Disease

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 12, 2026, 7:00 AM EST - 7 weeks ago

REPEAT/MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

Jan 9, 2026, 8:01 PM EST - 7 weeks ago

MindWalk Advances Universal Influenza Program with a Breakthrough Functional Insight

MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

Dec 15, 2025, 1:29 PM EST - 2 months ago

MindWalk Holdings Corp. (HYFT) Q2 2026 Earnings Call Transcript

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

Dec 15, 2025, 8:30 AM EST - 2 months ago

MindWalk Reports Record Growth and Announces Strategic Progress on Its AI Asset Pipeline

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

Dec 8, 2025, 8:30 AM EST - 3 months ago

MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Nov 13, 2025, 9:00 AM EST - 3 months ago

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 21, 2025, 8:28 AM EDT - 4 months ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Oct 17, 2025, 8:18 AM EDT - 4 months ago

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 15, 2025, 7:00 AM EDT - 4 months ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

Oct 9, 2025, 2:26 PM EDT - 5 months ago

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

MindWalk Announces Share Repurchase Program

Oct 9, 2025, 7:00 AM EDT - 5 months ago

MindWalk Announces Share Repurchase Program

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 22, 2025, 7:02 AM EDT - 5 months ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

Sep 15, 2025, 12:58 PM EDT - 6 months ago

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 15, 2025, 8:44 AM EDT - 6 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 3, 2025, 8:48 AM EDT - 6 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Sep 2, 2025, 8:01 AM EDT - 6 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 27, 2025, 8:22 AM EDT - 6 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 7 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Aug 6, 2025, 8:00 AM EDT - 7 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 12:39 PM EDT - 7 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 29, 2025, 8:28 AM EDT - 7 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 24, 2025, 8:22 AM EDT - 7 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 21, 2025, 8:28 AM EDT - 8 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 16, 2025, 8:05 AM EDT - 8 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 14, 2025, 8:01 AM EDT - 8 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 7, 2025, 9:00 AM EDT - 8 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jul 3, 2025, 8:19 AM EDT - 8 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 24, 2025, 7:02 AM EDT - 8 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 12, 2025, 8:01 AM EDT - 9 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

Jun 5, 2025, 8:01 AM EDT - 9 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 21, 2025, 8:49 AM EDT - 10 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 20, 2025, 8:28 AM EDT - 10 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

May 12, 2025, 8:01 AM EDT - 10 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Apr 11, 2025, 8:40 AM EDT - 11 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 12:59 PM EDT - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 28, 2025, 8:01 AM EDT - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 13, 2025, 7:02 AM EDT - 1 year ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 11, 2025, 10:17 PM EDT - 1 year ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Mar 5, 2025, 8:01 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 26, 2025, 8:01 AM EST - 1 year ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 24, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Feb 20, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 27, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 22, 2025, 7:02 AM EST - 1 year ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Jan 17, 2025, 8:01 AM EST - 1 year ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

IPA Announces Resignation of Chief Financial Officer

Dec 31, 2024, 7:56 PM EST - 1 year ago

IPA Announces Resignation of Chief Financial Officer

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

Dec 30, 2024, 10:03 PM EST - 1 year ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

NyseDayTrader
NyseDayTrader Mar. 2 at 8:13 PM
$HYFT Days of speculative rises are done with Bath. She needs to deliver!
0 · Reply
Crewm8te
Crewm8te Mar. 2 at 7:51 PM
$HYFT
0 · Reply
falcon_trader11
falcon_trader11 Mar. 2 at 7:06 PM
$HYFT
0 · Reply
Brandon70454
Brandon70454 Mar. 2 at 5:36 PM
$HYFT stay down until next week...I'll triple investment again.
0 · Reply
DollerADay
DollerADay Mar. 2 at 4:07 PM
$HYFT
0 · Reply
Brandon70454
Brandon70454 Mar. 2 at 3:35 PM
$HYFT tripled original investment...lets go!
0 · Reply
TheDuck23
TheDuck23 Mar. 2 at 2:22 PM
$HYFT going to be adding big time today
1 · Reply
NyseDayTrader
NyseDayTrader Mar. 2 at 9:42 AM
$HYFT
1 · Reply
Twills08
Twills08 Mar. 1 at 4:53 PM
$HYFT Company has been awfully quiet lately….
1 · Reply
PrimePorter
PrimePorter Mar. 1 at 7:51 AM
$HYFT
0 · Reply
Homerun416
Homerun416 Feb. 27 at 11:49 PM
$HYFT
0 · Reply
TheGoodestBoy
TheGoodestBoy Feb. 27 at 7:51 PM
$HYFT
0 · Reply
Homerun416
Homerun416 Feb. 27 at 4:48 PM
$HYFT
0 · Reply
Scam_Likely
Scam_Likely Feb. 27 at 4:12 PM
$HYFT A Reverse Split would mean the end of the ticket. Seriously. She needs to defend 1.00.
1 · Reply
RND120
RND120 Feb. 27 at 7:51 AM
$HYFT
0 · Reply
Uncle_Salty
Uncle_Salty Feb. 26 at 9:19 PM
$HYFT When was the last time the BOD or CEO Bath bought shares???? Too long. Bath's significant compensation verses what has been delivered is outrageous 🤨 I know I'm stating the obvious; I'm just bloody tired of Bath time-lines promised only to be repeatedly missed or forgotten. Particularly the run up to January 12!
1 · Reply
Ayalien
Ayalien Feb. 26 at 7:50 PM
$HYFT
0 · Reply
Scam_Likely
Scam_Likely Feb. 26 at 3:32 PM
$HYFT this reminds me a heavily diluting stock. Market goes up, we go down… market goes down… we go down.
1 · Reply
NyseDayTrader
NyseDayTrader Feb. 26 at 1:37 PM
$HYFT
0 · Reply
Twills08
Twills08 Feb. 26 at 12:59 PM
$CAPT $HYFT Both are holding the line, and so am I. Buy it, and forget it until it rises 300%. I have no problem with that plan.
1 · Reply
Tester87100
Tester87100 Feb. 26 at 7:50 AM
$HYFT
0 · Reply
StrongInvest
StrongInvest Feb. 25 at 7:59 PM
$HYFT My reliable little double tapper. IYKYK.
0 · Reply